Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19552555 | 0.85 | GAA (0.57) | POLBKDM4EATMGAAPLK1 | |
| SCHEMBL2344909 | 0.84 | GAA (0.71) | POLBGAAPLK1ALDH1A1RECQL | |
| SCHEMBL960781 | 0.83 | KDM4E (0.58) | POLBKDM4EATMGAAADRA1D | |
| SCHEMBL8628627 | 0.82 | POLB (0.67) | POLBKDM4EATMGAAALDH1A1 | |
| SCHEMBL21318305 | 0.82 | POLB (0.56) | POLBKDM4EATMGAAALDH1A1 | |
| SCHEMBL3478287 | 0.80 | ADRA1D (0.56) | POLBKDM4EATMGAAADRA1D | |
| SCHEMBL11393249 | 0.80 | KDM4E (0.55) | POLBKDM4EATMGAAADRA1D | |
| SCHEMBL21454987 | 0.80 | GAA (0.52) | POLBKDM4EATMGAAPLK1 | |
| SCHEMBL9189162 | 0.80 | MEN1 (0.64) | POLBKDM4EATMALDH1A1RECQL | |
| SCHEMBL13761443 | 0.80 | KDM4E (0.59) | POLBKDM4EATMADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553064-B1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20210252004-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | WEX MEDICAL LIMITED (HK) | 2021-08-19 | — | — | US | disclosed |
| US-10624896-B2 | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy | WEX MEDICAL LIMITED (HK) | 2020-04-21 | — | — | US | disclosed |
| EP-3553064-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190160074-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | WEX MEDICAL LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
| WO-2019002074-A1 | THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-03 | — | — | WO | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170000797-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | WEX MEDICAL LIMITED (HK) | 2017-01-05 | — | — | US | disclosed |
| US-20170000797-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | WEX MEDICAL LIMITED (HK) | 2017-01-05 | — | — | US | disclosed |
| US-7241769-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1036075-B1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | REDDYS LAB LTD DR (IN) | 2004-06-23 | — | — | EP | disclosed |
| US-6664411-B2 | Beta-aryl/alpha-oxysubstituted alkylcarboxylic acids of 4-oxo-or thiocarbonylchromenes or thiochromenes; antiobesity, -cholesterol - diabetic agents; agonists of peroxisome proliferator activated receptors; kidney disorders | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-16 | — | — | US | disclosed |
| US-6313113-B1 | AZOLIDINEDIONE DERIVATIVES, ANALOGUES, TAUTOMERIC FORMS, STEREOISOMERS, POLYMORPHS, SALTS AND SOLVATES; TREATING NON-INSULIN-DEPENDENT DIABETES MELLITUS | REDDY-CHEMINOR, INC. | 2001-11-06 | — | — | US | disclosed |
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1124807-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| EP-1036075-A1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-09-20 | — | — | EP | disclosed |
| US-6030973-A | TYPE II DIABETES (NON-INSULIN-DEPENDENT-DIABETES MELLITUS) POTENTIATION; EFFICIENCY; SIDE EFFECT REDUCTION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-02-29 | — | — | US | disclosed |
| WO-1999016758-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998045291-A1 | SUBSTITUTED THIAZOLIDINEDIONE AND OXAZOLIDINEDIONE HAVING ANTIDIABETIC, HYPOLIPIDEMIA AND ANTIHYPERTENSIVE PROPERTIES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624896-B2 | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy | SCN10A, SCN5A, SCN3A | POLB 4001/4885KDM4E 2996/4885ATM 3800/4885 |
| US-20170000797-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | SCN10A, SCN3A, SCN1A | POLB 3303/4885KDM4E 3623/4885ATM 3398/4885 |
| US-20210252004-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | SCN10A, SCN5A, SCN3A | POLB 4001/4885KDM4E 2996/4885ATM 3800/4885 |
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CYP11B1, CYP46A1, CYP51A1 | POLB 2887/4885KDM4E 2843/4885ATM 4435/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | POLB 4687/4885KDM4E 4395/4885ATM 2761/4885 |
| US-20190160074-A1 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | SCN10A, SCN5A, SCN3A | POLB 4001/4885KDM4E 2996/4885ATM 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.